English
Choose your country/region and language
Your experience may change as only information for the country or region you select will be presented.
Brain-derived Tau in Neurodegenerative Diseases
About 80% of the Tau protein found in plasma originates from peripheral tissues, creating a critical need to selectively measure Tau that originates in the central nervous system (CNS). Brain-derived Tau (BD-Tau) is produced exclusively in the brain and can be detected in the CNS and peripheral blood.
Research shows that measuring BD-Tau can accurately identify Alzheimer’s disease (AD)-specific neurodegeneration, distinguishing it from non-AD diseases (i.e., frontotemporal dementia, traumatic brain injury, stroke, multiple sclerosis)1,2
Request more info
This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.
We are working to create a brighter future for individuals affected with neurodegenerative diseases.
Discover more about our RUO BD-Tau assay and its potential applications.
%CV across the measurement range
pg/mL Limit of Detection
Detection of BD-Tau in all samples on both the DxI 9000 and Access 2 analyzers
All
BD-Tau
- Shows strong correlation to CSF Total Tau (T-Tau) for investigational purposes.
- Displays a significant association with AD-related pathology and cognition in research.
- Assists in research into risk stratification for research groups, exploring disease and treatment management.
What’s unique about the Beckman Coulter RUO assay?
- Fully automated for use on the DxI 9000 and Access 2 analyzers
- Streamlined workflow for clinical research labs
- Enhanced sensitivity and specificity with %CV <4% across the testing range
Assay Characteristic |
Access BD-Tau (RUO) |
| Assay format | Two-step sandwich |
| Recommended sample type(s) | Plasma (K2-EDTA) |
| Unit of measure | pg/mL |
| Analytical Measuring Range | 0.057 – 300 pg/mL |
| Open reagent pack stability | 2 to 10°C for 31 days |
| Open calibrator pack stability | 2 to 10°C for 31 days |
| Open QC vial stability | 2 to 10°C for 31 days |
| Sample volume (uptake) | Access 2 & DxI 9000: 55 µL |
| Time to first result (approximate) | Access 2: ~32 minutes DxI 9000: ~38 minutes |
| Imprecision (%CV) Within-Laboratory | Access 2: ~2.3-3.8% DxI 9000: ~1.9 – 2.8% |
We are committed to research that advances neurodegenerative disease diagnostics to make them more accessible to people around the world. Leveraging our history of IVD development, we are empowering cutting-edge research with high-quality, innovative assays that deliver accurate and affordable testing solutions at scale. Learn more about our comprehensive solutions.
BD-Tau and Neurodegenerative diseases
BD-Tau levels are correlated with increased levels of Amyloid beta plaques in the brain.
Studying BD-Tau may help to further research into AD pathology, flag samples from those with early-stage AD-pathology,
and aid in distinguishing AD from other forms of dementia.
Thank you for your request.
A Beckman Coulter representative will contact you shortly.
References:
1. Gonzalez-Ortiz F, Kirsebom B-E, Contador J, et al. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease. Nat Commun. 2024;15(1):2908. doi:10.1038/s41467-024-47286-5
2. Vlegels N, Gonzalez-Ortiz F, Knuth NL, et al. Brain-derived Tau for Monitoring Brain Injury in Acute Ischemic Stroke. medRxiv. November 19, 2023. doi:10.1101/2023.11.18.23298728
(2025-14798)
